Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
Our study identified significant AE signals for pola+BR through realworld disproportionality analysis data and analyzed the severity and clinical priority of these signals, which can assist clinicians in managing related AEs.
Authors
- Siliang Wang (ORCID: https://orcid.org/0000-0003-1228-869X)
- Yonggong Yang (ORCID: https://orcid.org/0000-0002-6475-2696)
- Jie Zhou (ORCID: https://orcid.org/0000-0003-3389-7515)
- Weihui Zhang (ORCID: https://orcid.org/0000-0002-3180-3004)
- Jinping Zhang (ORCID: https://orcid.org/0000-0002-8679-5988)
- Wenting Cai
- Mengying Liu (ORCID: https://orcid.org/0000-0001-7838-5519)
- Fang Wu
- Runyan Niu
- Xihui Xu
Institutions
- China Pharmaceutical University (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.3389/fphar.2025.1459067
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Chinese Pharmaceutical Association
- Nanjing University